ENHANCED SURGICAL RECOVERY PROGRAM PERIOPERATIVE GOAL DIRECTED THERAPY (PGDT) ECONOMIC BENEFIT
Author(s)
Okumura LM1, Riveros BS2, Lucchetta RC2, Rosim MP3, Nita ME4, Goodall G5, Ferreira CN6
1Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Market Access and Patient Engagement Solutions - MAPES, São Paulo, Brazil, 5Edwards Lifesciences SA, Nyon, Switzerland, 6Edwards Lifesciences Latam, São Paulo, Brazil
OBJECTIVES:: To estimate the economic benefit from Perioperative goal directed therapy (PGDT performed with ClearSight, a non-invasive hemodynamic monitoring strategy) in high-risk surgeries in Brazilian daily practice (Brazilian Supplementary Health System). METHODS:: We developed an exploratory economic analysis by creating a simple decision tree model. Randomized clinical trials evaluating PGDT as an intervention versus non-PGDT implementation as a control group were used as sources of clinical outcomes and benefits. Costs were extracted from a Brazilian supplementary health system-oriented study on the costs of perioperative complications. We projected 200 procedures for each hemodynamic monitoring strategy and calculated global costs, length of stay (LOS) and average costs per patient. No patient centric outcomes such as quality of life or opportunity costs derived from reduced LoS were captured in this analysis. RESULTS:: The total cost saving for PGDT versus non-PGDT was R$ 449.670 even after factoring the costs of materials for PGDT. There was also an average reduction in length of stay (LOS) of 1,95 days per patient. The effective cost saving per patient was R$ 2,248 with a reduction in morbidity of 56% for PGDT. CONCLUSIONS:: In the present exploratory study, we propose that PGDT has the potential to generate sufficient cost savings from avoidable post-surgical complications to significantly offset the costs of implementation for the Brazilian Supplementary Health System. This should be tested in future more stringent economic analysis as soon as upcoming data is published.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMD19
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders